FDA Warns on Xolair's (omalizumab) Serious Adverse Events: AttorneyOne Monitors and Keeps Consumers Informed

Share Article

On September 26, the FDA issued a safety communication on potential risks of cardiovascular and cerebrovascular serious adverse events to Xolair's (omalizumab) drug label. In light of this news, AttorneyOne, a recognized authority on law, updated the website providing detailed information to consumers.

Xolair: FDA Drug Safety Communication

Xolair: FDA Drug Safety Communication

we are determined to keep an eye on FDA announcements concerning Xolair (omalizumab) and inform the public

AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on Xolair (omalizumab).

The US FDA announced on September 26, that the Agency added information on potential risks of cardiovascular and cerebrovascular serious adverse events to Xolair's (omalizumab) drug label. Xolair (omalizumab) is used as an injectable drug to treat moderate to severe persistent allergic asthma in patients 12+ y.o. whose asthma symptoms are not controlled by inhaled corticosteroids.

FDA’s reason for the safety communication is based on an FDA review of safety studies which suggests a slightly increased risk of problems involving the heart and blood vessels supplying the brain among patients being treated with Xolair (omalizumab) than in those who were not treated with Xolair. Moreover, as the Agency cannot rule out a potential risk of cancer with this drug, the relative information was added to the Warnings and Precautions section of Xolair.

Taking into consideration the latest developments, AttorneyOne.com monitor daily and update the website providing accurate information on all relevant FDA safety alerts. Sean Burke, director of Media Relations at AttorneyOne.com, adds “we are determined to keep an eye on FDA announcements concerning Xolair (omalizumab) and inform the public. For that reason", he continues, "our focus should squarely fall on investigating these safety alerts and getting the word out.”

As the FDA recommends “Patients taking Xolair should continue to take the medication as prescribed and discuss any questions or concerns with their health care professionals.”

AttorneyOne.com has further information on Xolair (omalizumab) at the website including the latest major drug, medical products, and food law news.

Headquartered in San Diego, CA Attorney One was founded in 2004 and is not a law firm. They offer a nationwide legal service which helps consumers find the best representation for their legal needs. You can learn more about Attorney One at our website http://www.attorneyone.com. You can also find us on Facebook at http://www.facebook.com/AttorneyOne. Checkout earlier news from us at http://www.prweb.com/releases/2014/09/prweb12204940.htm

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sean Burke
Attorney One
+1 877-230-7343
Email >
@Attorney_One
Follow >
Visit website